ReWalk Received CE Mark for soft Exoskeleton-like Device
3 June, 2019
ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of patients with lower limb disability due to stroke
The news that ReWalk Robotics from Yokneam, Israel, received a CE clearance to market its ReStore Exo-Suitstock, hit the market with surprise and drove the company’s value in NASDAQ more than 20% up. Further more, the company estimated last week that the approval request it had submitted last February to the FDA, complies with the American regulator’s demands and will be approved in the coming months.
ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of patients with lower limb disability due to stroke. It is a first of its kind gait training solution. ReWalk CEO, Larry Jasinski, told Techtime that ReStore can a revolutionize post stroke gait training. ”We developed this design through collaboration with the Wyss Institute at Harvard. It was a unique opportunity to combine both our scientific and technical expertise.”
Stroke is a leading cause of disability. The UK stroke association estimates that approximately 17 million people worldwide affected by stroke each year. As many as 80% of stroke survivors suffer Locomotor Dysfunctions, such as asymmetrical step length, slow velocity, and altered bio-mechanical alignment. ReWalk is globally known for its rigid exoskeleton product, ReWalk Personal 6.0, designed to actively assist individuals with paralysis following a spinal cord injury.
The company announced that ReStore will be priced significantly below the ReWalk Personal 6.0. “The affordability and versatility of ReStore make it an attractive solution for a broader range of the rehabilitation cases than our previous technologies,” said Jasinski. To date, ReWalk has placed nearly 550 exoskeletons in 26 countries and trained more than 270 rehabilitation clinics to conduct exoskeleton training worldwide.